UPDATE 1-BTG says interventional medicine buys could boost sales to $1 bln
* Buys EKOS Corp, Nordion unit for combined initial $380 mln
* Adds liver cancer, DVT treatments
* Says lays foundation of $1 billion business
* Shares down 0.2 percent
By Paul Sandle
LONDON, May 23 (Reuters) - British pharmaceutical company BTG announced two deals on Thursday that it said could create an interventional medicine business with potential sales of $1 billion.
Chief Executive Louise Makin told Reuters the deals would more than double BTG's revenues in the fast-growing market of targeting specific areas rather than administering drugs to the whole body.
BTG added to its liver cancer treatments by agreeing to buy the targeted therapies division of Nordion Inc for about $200 million, adding Therasphere radioactive glass beads to its chemotherapy beads unit.
It is also buying EKOS Corp for an initial $180 million, plus up to $40 million in future payments, to gain a treatment for severe blood clots, which can be fatal if they cause a pulmonary embolism. Continued...